CRL on the way? Aca­dia re­ports a sur­prise hitch in its quest to ex­pand the mar­ket for Nu­plazid — shares rout­ed

5 years ago
FDA+

Mer­ck dis­card jumps straight to the top of the chart of the most ex­pen­sive drugs in the US at $1M-plus

5 years ago
Pharma

Cy­to­Dyn tries to squeeze pos­i­tive news out of a failed Covid-19 study — and shares take a beat­ing

5 years ago
R&D

Covid-19 roundup: Mer­ck and Ridge­back re­port ear­ly da­ta for an oral an­tivi­ral to fight the pan­dem­ic; Aus­tria pulls a ...

5 years ago
Coronavirus

Mount Sinai leas­ing of­fice space for out­pa­tient clin­ics, biotech re­search; Zol­gens­ma OK to be sold in UK, NICE says

5 years ago
News Briefing

Biotech IPO mar­ket looks to ramp back up as BMS part­ner Ike­na and its im­munome­tab­o­lism ther­a­pies eye pub­lic of­fer­ing

5 years ago
Financing

Anap­tys­Bio takes a beat­ing as its lead drug fails its first PhII test. And 5 more tri­als are near­ing a read­out

5 years ago
R&D

Stim­u­lus bill packs a wind­fall for FDA and Covid-19 drug, vac­cine de­vel­op­ers

5 years ago
FDA+

Gilead­'s Bik­tarvy build its case for long-term use with 4-year da­ta show­ing last­ing HIV sup­pres­sion

5 years ago
Pharma

Fur­ther set­ting the stage for go­ing pub­lic, Vivek Ra­maswamy’s Roivant read­ies a deal to buy up a Vant’s stock — ...

5 years ago
Deals

In a new set­back, Seres cites Covid im­pact af­ter de­cid­ing to shelve its lead mi­cro­bio­me can­cer pro­gram

5 years ago
R&D

Gilead­'s Kite keeps adding to CAR-T Yescar­ta's bag of tricks with FDA ap­proval in fol­lic­u­lar lym­phoma — a first

5 years ago
FDA+

Roche with­draws Tecen­triq in blad­der can­cer amid FDA's sweep­ing re­view on ac­cel­er­at­ed ap­provals

5 years ago
Pharma
FDA+

Mar­tin Shkre­li faces an­oth­er law­suit, this time from in­sur­er, al­leg­ing plans to cre­ate a mo­nop­oly for Dara­prim

5 years ago
People

The top 100 bio­phar­ma VCs, Bob Brad­way places $2B bet in can­cer, gene edit­ing pi­o­neer's new big idea, and more

5 years ago
Weekly

Jazz CEO Bruce Cozadd cam­paigned for 6 months to buy GW Phar­ma. A 90% pre­mi­um sealed the deal — along with $17.6M ...

5 years ago
Deals

Covid-19 roundup: RE­COV­ERY tri­al halts re­cruit­ment for colchicine study af­ter find­ing ‘no con­vinc­ing ev­i­dence’; ...

5 years ago
Coronavirus

Seagen warns in­vestors against TRC Cap­i­tal’s lat­est 'mi­ni-ten­der of­fer'; BeiGene goes af­ter a new in­di­ca­tion for ...

5 years ago
News Briefing

Not 3 weeks af­ter tak­ing Hu­ma­cyte pub­lic, Ra­jiv Shuk­la launch­es an­oth­er blank check com­pa­ny

5 years ago
Financing

Genen­tech gains clin­i­cal de­vel­op­ment ex­ec by ap­point­ing Lil­li Petruzzel­li; Paul Sekhri caps event­ful week, nam­ing ...

5 years ago
Peer Review

Covid vac­cine roundup: US vac­cine sup­plies grow, but ex­perts warn of po­ten­tial hic­cups in sup­ply chain; Emer­gent ...

5 years ago
Manufacturing

How does Paul Hud­son's $13.5M comp pack­age stack up against oth­er CEOs? He's in the 'first quar­tile'

5 years ago
People

Pfiz­er's trou­ble-prone McPher­son plant — now ramp­ing up vac­cine sup­plies — was cit­ed for con­tin­u­ing vi­o­la­tions in ...

5 years ago
Manufacturing

Ab­b­Vie of­floads UK site for $119M in sale to Chi­nese cell and gene ther­a­py play­er Phar­maron

5 years ago
Outsourcing
Cell/Gene Tx
First page Previous page 725726727728729730731 Next page Last page
A service from the Financial Times